Market Place
Sourcing Support
Abacus & Mirum Partner To Commercialize LIVMARLI In Nordic
10 Sep 2024 //
CONTRACT PHARMA
Mirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older
25 Jul 2024 //
BUSINESSWIRE
Mirum`s LIVMARLI Long-Term ALGS, PFIC Data At EASL
06 Jun 2024 //
BUSINESSWIRE
Mirum Pharma announces positive CHMP opinion for Livmarli oral solution
03 Jun 2024 //
PHARMABIZ
Mirum`s LIVMARLI Gets Positive CHMP Opinion For PFIC From 3 Months
31 May 2024 //
BUSINESSWIRE
Mirum LIVMARLI PFIC Data Published In The Lancet
07 May 2024 //
BUSINESSWIRE
Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
07 May 2024 //
BUSINESSWIRE
Mirum LIVMARLI Receives Positive Reimbursement Recommendation by Canada
02 Apr 2024 //
BUSINESSWIRE
Mirum Pharmaceuticals Showcases Five New LIVMARLI (maralixibat)
23 Jun 2023 //
BUSINESSWIRE
Survival Data from Mirum’s LIVMARLI Alagille Syndrome Program Published
14 Jun 2023 //
BUSINESSWIRE
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule
10 May 2023 //
BUSINESSWIRE
Mirum Announces Label Expansion for LIVMARLI in the United States
15 Mar 2023 //
BIOSPACE
Mirum Pharmaceuticals’ LIVMARLI Approved by the European Commission
13 Dec 2022 //
BUSINESSWIRE
CANbridge Announces Encouraging Development in Maralixibat/LIVMARLI
26 Oct 2022 //
BUSINESSWIRE
Rare Liver Disease Wins Mount as Mirum`s PFIC Trial Meets Endpoint - Updated
26 Oct 2022 //
BIOSPACE
Positive Topline Data Announced from Mirum’s LIVMARLI Phase 3 MARCH Study
24 Oct 2022 //
BUSINESSWIRE
Mirum Pharma Announces Positive CHMP Opinion for LIVMARLI Oral Solution
14 Oct 2022 //
BUSINESSWIRE
Mirum Presents LIVMARLI Data & Alagille Syndrome Caregiver Burden Analysis
12 Oct 2022 //
BUSINESSWIRE
Mirum Pharmaceuticals to Present LIVMARLI (maralixibat) Analyses
05 Oct 2022 //
BUSINESSWIRE
Mirum Pharmaceuticals to Present LIVMARLI Analyses and Host a Symposium
05 Oct 2022 //
BUSINESSWIRE
Mirum Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 Aug 2022 //
BUSINESS WIRE
Mirum Pharmaceuticals Announces Pricing of Public Offering of Common Stock
09 Aug 2022 //
BUSINESSWIRE
Mirum Pharmaceuticals Announces Commencement of Public Offering of Common Stock
09 Aug 2022 //
BUSINESSWIRE
First Patient Dosed in CAN108 EMBARK PII Study in Biliary Atresia in China
14 Jul 2022 //
BIOSPACE
Mirum Pharma to Showcase LIVMARLI Data at EASL and ESPGHAN Annual Congresses
13 Jun 2022 //
BUSINESSWIRE
CANbridge Pharma`s CAN108 NDA/ORD for Alagille Syndrome Accepted by Taiwan FDA
28 Mar 2022 //
BUSINESSWIRE
Mirum Pharma Reports Q4 and Year-End 2021 Financial Results
09 Mar 2022 //
BUSINESSWIRE
Mirum Pharmaceuticals to Present at SVB Leerink 11th Annual Conference
09 Feb 2022 //
BUSINESSWIRE
CANbridge Pharmaceuticals` CAN108 NDA for Alagille Syndrome Accepted by NMPA
18 Jan 2022 //
BUSINESSWIRE
Mirum Pharmaceuticals to Present LIVMARLI (maralixibat)
06 Dec 2021 //
PRESS RELEASE
Mirum Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher
17 Nov 2021 //
BUSINESSWIRE
Six-Year Natural History Comparison with Mirum’s LIVMARLI (maralixibat)
15 Nov 2021 //
BUSINESSWIRE
Mirum Pharma Reports Q3 2021 Financial Results and Provides Business Update
15 Nov 2021 //
BUSINESSWIRE
FDA approves Mirum Pharma`s first treatment for rare pediatric bile duct disease
30 Sep 2021 //
ENDPTS
FDA Action Alert: Mirum and Kite/Gilead
27 Sep 2021 //
BIOSPACE
Takeda bags Japanese rights to maralixibat; Boehringer acquires Abexxa Biologics
21 Sep 2021 //
ENDPTS
Mirum Pharmaceuticals Submits European MAA for Maralixibat in Alagille Syndrome
13 Sep 2021 //
BUSINESSWIRE
Mirum Pharma to Showcase Analyses From Its Rare Liver Disease Programs at ILC
16 Jun 2021 //
BUSINESSWIRE
Mirum Announces Completion of Rolling NDA Submission for Maralixibat
01 Feb 2021 //
BUSINESSWIRE
Mirum Announces European Medicines Agency Validation of the Marketing
30 Nov 2020 //
BUSINESSWIRE
Mirum Broadens Expanded Access Program for Maralixibat in Alagille Syndrome
05 Nov 2020 //
PRESS RELEASE
Mirum Broadens Expanded Access Program for Maralixibat in Alagille Syndrome
05 Nov 2020 //
BUSINESSWIRE
Mirum Pharmaceuticals to Present Maralixibat Data and Host Symposium
26 Oct 2020 //
NEWS
Mirum Preps Rolling NDA for ALGS Candidate Maralixibat
01 Sep 2020 //
BIOSPACE
Mirum Pharmaceuticals Presents Maralixibat Five-Year Transplant-Free Survival
28 Aug 2020 //
BUSINESSWIRE
Mirum’s Maralixibat Demonstrates Transplant-Free Survival for Pediatric Patients
02 Jun 2020 //
BUSINESSWIRE
Mirum’s Maralixibat Demonstrates Transplant-Free Survival for Pediatric Patient
01 Jun 2020 //
YAHOO
Mirum spells out plans to turn Shire discards into orphan liver drug successes
24 Jun 2019 //
ENDPTS
Mirum scoops $120M to take ex-Shire drug into phase 3
06 Nov 2018 //
FIERCE BIOTECH
